CJC-1295 vs Dulaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Dulaglutide |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. |
| Best For |
What They Have in Common
CJC-1295, Dulaglutide are both commonly used for:
Key Differences
Unique to CJC-1295:
Detailed Analysis
Commonalities
Both CJC-1295 and Dulaglutide are commonly used for Fat Loss.
Which Should You Choose?
Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.
Ready to Learn More?
Looking for trusted sources?